*Michigan Center for Translational Pathology
†Department of Pathology
§Howard Hughes Medical Institute
∥Department of Urology
¶Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI
‡Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH
This study is supported in part by Department of Defense (PC040517, W81XWH-06-1-0224), the National Institutes of Health (Prostate SPORE P50CA69568, RO1 CA102872), and the Early Detection Research Network (UO1 CA111275-01). A.M.C. is supported by a Clinical Translational Research Award from the Burroughs Welcome Foundation and an award by the Doris Duke Charitable Foundation.
Disclosure: The University of Michigan has filed a patent on ETS gene rearrangements in prostate carcinoma, on which A.M.C. is one of the coinventors, and the diagnostic field of use has been licensed to Gen-Probe Incorporated. Gen-Probe has not played a role in the design and conduct of the study, nor in the collection, analysis, or interpretation of the data, and no involvement in the preparation, review, or approval of the manuscript. A.M.C. serves as a consultant to Gen-Probe Incorporated.
Correspondence: Rajal B. Shah, MD, Urologic Pathology, Caris Pathology, 6655 North MacArthur Boulevard, Irving, TX 75039 (e-mail: [email protected]).
Current address of the author Rajal B. Shah: Caris Diagnostics, Irving, TX 75039.
Ming Zhou and Rajal B. Shah share senior authorship.